Sood N, Turcotte SE, Wasilewski NV, Fisher T, Wall T, Fisher JT, Lougheed MD. Small-airway obstruction, dynamic hyperinflation, and gas trapping despite normal airway sensitivity to methacholine in adults with chronic cough. The clinical relevance of cough during methacholine challenge in individuals with normal airway sensitivity is unknown. We compared responses of individuals with chronic cough who cough during high-dose methacholine bronchoprovocation and have normal versus increased airway sensitivity to healthy controls. Fifteen healthy participants (CONTROL) aged 26 Ϯ 7 yr (mean Ϯ SD) and 32 participants aged 42 Ϯ 14 yr with chronic cough and suspected asthma completed high-dose methacholine challenge testing. Three participants who did not cough and had normal airway sensitivity were excluded. Spirometry and lung volumes were compared at the maximum response (MAX) among 1) ASTHMA [n ϭ 15, provocative concentration of methacholine causing a 20% fall in forced expiratory volume in 1 s (FEV1) from baseline (PC20) 4.71 Ϯ 1.37 mg/ml], 2) methacholine-induced cough with normal airway sensitivity (COUGH, n ϭ 14, PC20 41.2 Ϯ 18.7 mg/ml for 3 participants with a measurable PC20), and 3) CONTROL (n ϭ 15; PC20 93.4 Ϯ 95.4 mg/ml for 4 participants with a measurable PC20). Esophageal pressure-derived pulmonary mechanics were compared at MAX for the ASTHMA and COUGH groups. From baseline to MAX, FEV1 and forced expiratory flow between 25% and 75% of forced vital capacity decreased more in ASTHMA (Ϫ36.2 Ϯ 3.8 %pr; Ϫ47.1 Ϯ 6.9 %pr, respectively) than COUGH (Ϫ12.2 Ϯ 3.0 %pr (P Ͻ 0.001); Ϫ24.7 Ϯ 6.5 %pr (P Ͻ 0.001), respectively) and CONTROL (Ϫ13.7 Ϯ 2.0 %pr (P Ͻ 0.001); Ϫ32.8 Ϯ 5.4 %pr (P Ͻ 0.017), respectively). In both ASTHMA and COUGH, inspiratory capacity decreased by 500 -800 ml, and functional residual capacity and residual volume increased by~800 ml. Individuals with COUGH develop dynamic hyperinflation and gas trapping comparable to individuals with ASTHMA despite less bronchoconstriction and smaller reductions in mid-to-late expiratory flows, which leads us to believe that COUGH is a distinct phenotype.
INTRODUCTION
Cough is one of the most common reasons for a visit to a family physician, and understanding of the physiology, pathophysiology, and therapy of cough continues to evolve (42) . Asthma is one of the most common causes of chronic cough lasting 8 wk or more (25, 26, 58) . Chronic cough can also be caused by other conditions characterized by eosinophilic airway inflammation, including eosinophilic bronchitis (22) , atopic cough (21) , and cough variant asthma. Cough variant asthma is a term used to describe individuals whose sole or predominant symptom of asthma is cough (1, 48) . Individuals with paroxysmal cough without wheeze or dyspnea were first reported in the 1970s (10, 23) . The pathophysiologic differences between classic asthma, cough variant asthma, eosinophilic bronchitis, and atopic cough are poorly understood but may relate to differences in small airway function (65) .
During spontaneous and methacholine-induced bronchoconstriction in asthma, expiratory flow limitation leads to dynamic hyperinflation, gas trapping, and increased residual volume (RV) (38, 53, 54) . In healthy subjects, a deep inspiration causes bronchodilation with resultant improvement in flow limitation and gas trapping (54) . This bronchodilating effect of deep inspirations is impaired in individuals with asthma (54) . In healthy subjects, a deep inspiration also has bronchoprotective effects, whereby increased lung volume causes bronchodilation and subsequent refractoriness to bronchoconstriction (30) . Some have suggested that the fundamental pathophysiologic basis for airway hyperresponsiveness in asthma is impairment of the bronchoprotective effect of deep inspirations (18, 30) , which is associated with airway hyperresponsiveness (61) . Matsumoto et al. (41) have recently shown that, compared with classic asthma, individuals with cough variant asthma are less sensitive, less reactive, wheeze less frequently, and cough more during methacholine challenge. Other reports suggest children with cough variant asthma are less reactive (43) and have a reduced maximal response (29, 67) but similar sensitivity to methacholine compared with children with classic asthma (43, 67, 68) . In healthy subjects, methacholine-induced cough is associated with a preserved bronchodilating effect of a deep inspiration (50) . Compared with healthy individuals undergoing methacholine challenge, subjects with classic asthma have a blunted cough response (51) , whereas subjects with cough variant asthma have an increased cough response (52) . Anecdotally, we have noted small increases in positive end-expiratory esophageal pressure and normalization of pressures following a deep inspiration and cough in subjects with normal airway sensitivity, whose predominant response to methacholine is cough. We suspect this is a clinically relevant pathophysiologic mechanism of chronic cough, mediated by small airways obstruction and gas trapping. Furthermore, we hypothesize that the normal airway sensitivity in these individuals relates to preservation of the bronchoprotective effect of a deep inspiration, which precedes a cough.
We sought 1) to determine whether individuals with methacholine-induced cough with normal airway sensitivity (COUGH) develop small airways obstruction, dynamic hyperinflation, and gas trapping during high-dose methacholine challenge, and 2) to compare dynamic mechanical responses to high-dose methacholine challenge in patients with chronic cough and suspected classic asthma or cough variant asthma between individuals with and without increased airway sensitivity and healthy normal individuals without chronic cough or asthma. Some of these results have been previously reported in the form of abstracts (36, 37) .
METHODS

Participants.
Patients referred to a tertiary care cough clinic were invited to participate if they had chronic cough because of suspected or proven classic asthma (5) or cough variant asthma (1, 48) . Healthy individuals aged 18 -65 yr of age with no history of asthma, allergies (seasonal or otherwise), rhinitis/sinusitis, eczema, and/or chronic cough were recruited from Kingston's population using print advertisements. Exclusion criteria included 1) an asthma exacerbation within the previous 4 wk, 2) inability to perform acceptable quality spirometry, 3) medical contraindications to methacholine challenge testing (10), 4) smoking history in excess of 10 pack years, and 5) asymptomatic airway hyperresponsiveness to methacholine. Study approval was obtained from the Queen's University Health Sciences Research Ethics Board.
Study design. After informed consent, participant eligibility was verified (before testing) by detailed medical history and screening for exclusion criteria. The healthy individuals completed the self-administered comorbidity questionnaire (60) to assess any existing comorbidities. Participants had their exhaled fraction of nitric oxide measured to assess airway inflammation, if present. Subjects then completed baseline pulmonary function testing, including spirometry and body plethysmography. These were followed by a high-dose methacholine challenge testing ( Fig. 1) . Additionally, participants with chronic cough completed sputum induction for measurement of inflammatory cells and capsaicin challenge testing on a separate visit. Bronchodilators were withheld before testing as recommended by the American Thoracic Society guidelines (11) .
Plethysmographic measurements were measured at baseline, after inhalation of nebulized normal saline (0.9%), and at maximum response to methacholine (MAX). MAX was defined as any of the following: a decline in forced expiratory volume in 1 s (FEV1) to 50% of the baseline value, the mean value of FEV 1 on a response "plateau" (defined as a change in FEV 1 of Ͻ5% over two or more dose steps after a fall of Ͼ10% from the baseline value), the change in FEV 1 after the highest methacholine dose had been delivered (256 mg/ml dose), or the change in FEV1 at cessation of testing at the participant's request. Balloon-tipped catheters were positioned in a subset of consenting participants to record esophageal pressures during a subsequent visit.
In these participants, steady-state breathing pattern was measured at baseline, after inhalation of nebulized normal saline, and at MAX. Cough was defined as an audible expiratory maneuver against a closed glottis (9, 45) , and a coughing "bout" was defined as a prolonged series of expulsive efforts, either after a single breath or with several breaths interspersed (31) .
Methacholine challenge testing. Participants inhaled doubling doses of methacholine chloride (Methapharm, Inc., Brantford, Canada) using a standardized high-dose tidal breathing protocol (64) as previously described (35, 38 repeated occasionally to ensure they met American Thoracic Society standards. Capsaicin challenge testing. Capsaicin (Sigma Chemical Co., St. Louis, MO) challenge testing was performed using a standardized protocol (13, 16) via a nebulizer (model 646; DeVilbiss Health Care, Inc., Somerset, PA) limited to an inspiratory flow of 0.5 l/s and driven by a KoKo Dosimeter (Pulmonary Data Services, Inc., Louisville, CO). The number of coughs was recorded manually for 15 s following each dose. The challenge was terminated when the patient coughed five or more times or the last dose had been administered.
Sputum induction and examination. Sputum induction and examination were performed according to the Hargreave method (55) (56) (57) using aerosolized hypertonic saline generated by a Universal III ultrasonic nebulizer (Flaem Nuova S.P.A., Brescia, Italy).
Exhaled nitric oxide measurement. The fraction of exhaled nitric oxide was measured using a NIOX MINO (Aerocrine AB, Sweden) in accordance with American Thoracic Society/European Respiratory Society standards (2) before bronchoprovocation testing to avoid confounding of results. After inhalation of nitric oxide-free air, subjects exhaled without nose clips applied from total lung capacity at a flow rate of 50 ml/s against a flow resistance created by the device to avoid nasal airflow contamination.
Pulmonary function and mechanics measurements. Spirometry, lung volumes, and specific airway resistance were performed using a 6200 Autobox D L (SensorMedics, Yorba Linda, CA) according to recommended techniques (63) . Panting frequency was standardized to 1 Hz (59). Inspiratory capacity was measured from the flow-volume loop. Predicted values for spirometry, lung volumes, and airway resistance were those of Morris and coworkers (46), Goldman and Becklake (24) , and Briscoe and Dubois (6), respectively. Participants were trained how to perform the lung volume maneuvers by a Registered Respiratory Therapist during the baseline testing.
Esophageal pressure (Pes) was recorded using a balloon-tipped catheter system as previously described (35, 38) . After data collection, the pressure tracings were cleaned to remove any confounding swallows and cough reading and to ensure a stable tracing. Breathing pattern was measured with a no. 3 Fleisch pneumotachograph (A. Fleisch, Gruenstrasse, Germany) and computerized data acquisition system (Advanced CODAS, Harvard Apparatus, Saint Laurent, Canada).
Statistical analysis. Results are expressed as mean Ϯ SD unless otherwise stated. Analyses were performed using the conventional level of statistical significance (P Ͻ 0.05). Between-group comparisons were made using ANOVA with Bonferroni correction for multiple comparisons and Kruskal-Wallis tests with post hoc Mann-Whitney U tests (for three groups) or unpaired t-tests with equal variances not assumed and two-sided Fisher's exact tests (for two groups). Within-participant changes were examined using paired t-tests. Analysis was done using SPSS Version 20.0.0 (IBM, Chicago, IL).
RESULTS
Participants.
Of the 32 enrolled participants with cough, 15 had a provocative dose causing a 20% decline in FEV 1 from baseline (PC 20 ) Յ 16 mg/ml, and 17 individuals had normal airway sensitivity (PC 20 Ͼ 16 mg/ml). Three subjects who did not cough in response to methacholine and had normal airway sensitivity were excluded from analyses ( Fig. 2A ). For the healthy participants, out of the 37 enrolled participants, 15 were considered eligible and included in the analyses (Fig. 2B ). The characteristics of 44 participants included in the analysis are summarized in Table 1 . Participants with asthma (ASTHMA, n ϭ 15) were significantly younger than healthy participants (CONTROL, n ϭ 15) and participants with COUGH (n ϭ 14). Two participants in ASTHMA and one CONTROL participant were exsmokers (7, 8, and 5 pack-year history, respectively). Sputum eosinophil levels and cough sensitivity to capsaicin (coughing five or more times) were normal in ASTHMA and COUGH. At baseline, the ASTHMA group showed significantly higher forced residual capacity [%predicted (%pr)] and RV (%pr) compared with CONTROL group. The COUGH had a significantly lower baseline inspiratory capacity compared with CONTROL.
Responses to high-dose methacholine. Group responses to high-dose methacholine are shown in Table 2 and 3 and Figs. 3 and 4. FEV 1 decreased 35.7 Ϯ 3.2%, 12.3 Ϯ 3.3%, and 13.7 Ϯ 2.0% from baseline to MAX in the ASTHMA, COUGH, and CONTROL groups, respectively (P Ͻ 0.001). In the ASTHMA group, the increase in sRaw (%pr) was significantly higher compared with the COUGH and CONTROL groups (P Ͻ 0.001). The ASTHMA and CONTROL groups developed significantly greater reductions in mid-to-late expiratory flows compared with the COUGH group. Despite this, gas trapping and dynamic hyperinflation were comparable between the COUGH and ASTHMA groups, with increases in forced residual capacity and RV of 800 ml at MAX in both groups.
Pes-derived pulmonary mechanics. In the subset of participants who had esophageal balloons placed (n ϭ 15), the COUGH subgroup was significantly older than the ASTHMA subgroup (Table 4 ). Two individuals with ASTHMA had previous smoking histories. There were no other significant differences in participant characteristics between these two groups at baseline. Table 5 summarizes the subgroup pulmonary function responses to high-dose methacholine. The ASTHMA subgroup developed greater reductions in FEV 1 and mid-to-late expiratory flows compared with the COUGH subgroup, yet there were no significant differences between groups in gas trapping or dynamic hyperinflation. Table 6 outlines the mechanical responses in the subgroups of participants in whom esophageal balloon measurements were recorded. There were no significant differences between these subgroups at baseline or at MAX. The change in the mechanical responses from baseline to MAX was also not significantly different between these subgroups. Inspired tidal volume did not significantly change in either subgroup ( Table  6 ). Tidal swings of Pes increased in both the ASTHMA and COUGH subgroups by 5.85 Ϯ 1.3 cmH 2 O (mean Ϯ SE; P ϭ 0.005) and 4.81 Ϯ 1.3 cmH 2 O (P ϭ 0.009), respectively. At maximal bronchoconstriction, the Pes change required for a given inspiratory tidal volume (Pes/VT I ) increased by 11.2 Ϯ 2.4 cmH 2 O/l (P ϭ 0.003) in the ASTHMA subgroup and by 10.9 Ϯ 2.6 cmH 2 O/l (P ϭ 0.004) in the COUGH subgroup. Pes (% maximal inspiratory pressure) increased 13.3 Ϯ 2.8% (P ϭ 0.003) in the ASTHMA subgroup and 12.7 Ϯ 4.3% (P ϭ 0.021) in the COUGH subgroup. The dynamic end-expiratory lung volume (EELV dyn ) increased in the ASTHMA (0.84 Ϯ 0.21 liters; P ϭ 0.008) and COUGH subgroups (0.87 Ϯ 0.33 liters; P ϭ 0.033). Concomitantly, the inspiratory threshold load increased significantly in both the ASTHMA and COUGH subgroups, by 6.9 Ϯ 2.7 cmH 2 O (P ϭ 0.041) and 3.8 Ϯ 0.9 cmH 2 O (P ϭ 0.003), respectively.
Pulmonary function and mechanics before and after selected coughs. Table 7 summarizes the pulmonary function and mechanics before and after selected coughing bouts. These coughing bouts were selected based on the recordings from esopha-geal balloon studies only in the COUGH group. After "cleaning" the data from the esophageal balloon studies, data from two subjects could not be reliably scored and thus, were not included in the analysis. Therefore, only six out of the eight COUGH subjects with analyzable Pes tracings before and after coughing bouts were used in the analysis. Following the coughing bouts, there were statistically significant improvements in small airway obstruction, Pes at end-expiration, and dynamic intrinsic positive end-expiratory pressure. Representative esophageal pressure tracings from two participants depicting changes following deep inspirations and cough are shown in Fig. 5 .
DISCUSSION
This study demonstrated that individuals with chronic cough who cough during methacholine challenge but have normal airway sensitivity to methacholine develop substantial dynamic hyperinflation and gas trapping (of~800 ml) during high-dose methacholine challenge. The degree of dynamic hyperinflation and gas trapping observed was comparable to adults with asthma who have mild airway hyperresponsiveness to methacholine, despite declines in FEV 1 and mid-to-late expiratory flows comparable to healthy individuals. Resultant dynamic mechanical responses included increases in the inspiratory threshold load and positive end-expiratory pressure. In individuals with marked coughing in response to methacholine, statistically significant improvements in mid-to-late expiratory flows and positive end-expiratory pressure were noted following coughing bouts.
By definition, the three groups studied differed in airway sensitivity to methacholine; only three COUGH and four CONTROL participants had a measurable PC 20 . The three groups were well matched for age and sex, and the ASTHMA and COUGH groups were well matched for comorbid conditions associated with chronic cough, airway inflammation, and cough sensitivity. Although still within normal ranges, baseline FEV 1 /forced vital capacity was lower and FRC and RV were higher in the ASTHMA group.
The clinical relevance of cough during methacholine inhalation challenge tests in absence of an abnormal methacholine PC 20 remains speculative, suggesting a continuum of small airway gas trapping as exhibited for those with cough alone. Negative MCh (PC 20 >16mg/mL) (n=17)
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Healthy Participants Enrolled (n = 37) Excluded (n = 10) n = 7: Allergies, rhinitis/sinusitis n = 3: No show n = 7: >20% fall in FEV 1 from baseline at MCh dose ≤16mg/mL n = 2: >20% fall in FEV 1 from baseline after isotonic saline n = 2: Unable to perform repeatable spirometry measures n = 1: Reversible obstruction at baseline Whether this continuum represents age-related changes in small airway function or "pre-" pathology indicators remains unknown. Thus, our results support the notion that cough during bronchoprovocation testing is an important clinical observation worth documenting. Others have come to similar conclusions (32) . For example, cough with normal airway sensitivity has also been described during mannitol challenge (32) and hypertonic saline and hypertonic histamine challenges (33) . Koskela et al. (33) hypothesized that although cough during inhalation challenge with isotonic histamine and meth- Values are means Ϯ SD. %pr, % predicted; BMI, body mass index; C5, coughed five or more times; eNO, exhaled nitric oxide; FEF25%-75%, forced expiratory flow between 25% and 75% of FVC; FEF50%, forced expiratory flow at 50% of FVC; FEF75%, forced expiratory flow at 75% of FVC; FVC, forced vital capacity; FRC, functional residual capacity; GERD, gastresophageal reflux disease; IC, inspiratory capacity; PC20, provocative dose causing a 20% decline in FEV1 from baseline; PNDS, postnasal drip syndrome; sRaw, specific airway resistance; RV, residual volume; N/A, not applicable; TLC, total lung capacity. Bolded values indicate significance differences. P values from one-way ANOVA with Bonferroni correction for multiple corrections, except for *P values using unpaired t-tests with equal variances not assumed. Values are means Ϯ SE. %pr, % predicted; FEF25%-75%, forced expiratory flow between 25% and 75% of FVC; FEF50%, forced expiratory flow at 50% of FVC; FEF75%, forced expiratory flow at 75% of FVC; FRC, functional residual capacity; FVC, forced vital capacity; IC, inspiratory capacity; RV, residual volume; sRaw, specific airway resistance; Bolded values indicate significance differences. P values from one-way ANOVA with Bonferroni correction for multiple comparisons.
acholine is a physiologic response to bronchoconstriction, cough during challenge tests in the absence of bronchoconstriction represents a distinct pathophysiologic phenomenon with a distinct mechanism.
Our findings of lower reductions in mid-to-late expiratory flows, with dynamic hyperinflation and gas trapping comparable with ASTHMA in individuals with chronic cough are intriguing. Using traditional bronchoprovocation testing, these individuals would be classed as having normal airway physiology (i.e., not asthma). A plausible diagnostic consideration would be eosinophilic bronchitis. Notably, sputum differential cell counts were obtained in the majority of ASTHMA and COUGH participants, and the mean proportion of eosinophils was less than 2% in both groups. This finding must be interpreted in the context of current anti-inflammatory controller therapy. Over 50% of the ASTHMA participants and approximately two-thirds of the COUGH participants were not using inhaled corticosteroids as maintenance therapy. Thus, we cannot label our participants as having eosinophilic bronchitis, nor can we attribute their methacholine-induced cough to current eosinophilic airway inflammation.
If classic asthma, cough variant asthma, and eosinophilic bronchitis without asthma represent conditions along a continuum of eosinophilic airway disorders (15, 65) , then methacholine-induced cough (with gas trapping and dynamic hyperinflation) in the absence of increased airway sensitivity to methacholine may represent another "phenotype" along that continuum. Recognition of such an entity may have important diagnostic and therapeutic implications. These may include performing other challenge tests (such as an exercise-induced asthma challenge or mannitol challenge) to assess responsiveness to other agents, or a therapeutic trial of inhaled or oral corticosteroids and/or bronchodilators.
The mechanisms of cough in asthma remain controversial and have been recently reviewed (47, 65) . Candidate mechanisms include eosinophilic airway inflammation and mast cell activation (47) . Our study provides novel data to suggest that preservation of the bronchodilating, plus or minus the bronchoprotective effect(s) of deep inspirations, distinguish individuals with methacholine-induced cough with normal airway sensitivity from those with classic asthma and cough variant asthma (39) . The rise in esophageal pressure recordings at end-expiratory pressure before coughing bouts, with a return to previous levels following a deep inspiration and cough, is consistent with the description of the bronchodilating effect of a deep inspiration in normal individuals (62) . Using partial flow-volume curves (which avoid deep inspirations) and full flow-volume curves (which contain deep inspira- Values are means Ϯ SE. %pr, % predicted; FEF25%-75%, forced expiratory flow between 25% and 75% of FVC; FEF50%, forced expiratory flow at 50% of FVC; FEF75%, forced expiratory flow at 75% of FVC; FRC, functional residual capacity; FVC, forced vital capacity; IC, inspiratory capacity; RV, residual volume; sRaw, specific airway resistance. Bolded values indicate significance differences. P values from one-way ANOVA with Bonferroni correction for multiple comparisons. Values are means Ϯ SD. Bolded values indicate significance differences. %pr, % predicted; BMI, body mass index; C5, coughed five or more times; eNO, exhaled nitric oxide; FEF25%-75%, forced expiratory flow between 25% and 75% of FVC; FEF50%, forced expiratory flow at 50% of FVC; FEF75%, forced expiratory flow at 75% of FVC; FRC, functional residual capacity; FVC, forced vital capacity; GERD, gastresophageal reflux disease; IC, inspiratory capacity; N/A, not applicable; PC20, provocative dose causing a 20% decline in FEV1 from baseline; PEFR, peak expiratory flow rate; RV, residual volume; sRaw, specific airway resistance; TLC, total lung capacity; UACS (formerly PNDS), upper airway cough syndrome (formerly postnasal drip syndrome). P values from unpaired t-tests with equal variances not assumed except *two-sided Fisher's exact tests; †n ϭ 3; ‡n ϭ 4; §n ϭ 6; ¶n ϭ 7. **Statistics shown are for % predicted values.
viewed (8, 19, 65) . Potential pathways include 1) altered cough reflex sensitivity, potentially because of increased expression of transient receptor potential vanilloid-1 channels in airway C-fibers, 2) direct stimulation of rapidly adapting receptors because of the mechano-stimulus provided by bronchoconstriction, 3) direct stimulation of cough receptors by punctate mechanical stimuli or protons (7) , and/or 4) indirect stimulation of transient receptor potential vanilloid-1 or rapidly adapt-ing receptors via osmotic changes in airway surface lining and resultant mediator release (65) .
Increased cough reflex sensitivity in cough variant asthma compared with asthma has been reported by Dicpinigaitis et al. (14) but not replicated by others (12, 20) . These differences may relate to challenges in performing cough challenge tests and/or lack of standardization of protocols (44) . Our findings of normal capsaicin sensitivity in both ASTHMA and COUGH groups cannot be directly compared with the aforementioned studies, because our ASTHMA group included both classic asthma and cough variant asthma.
The receptor(s) and afferent pathway(s) triggering cough cannot be directly determined from our study. Based upon landmark studies in animal models by Widdicombe (66) , rapidly adapting receptor activation directly by bronchoconstriction is widely accepted as a primary mechanism of bron- choconstriction-mediated cough. Our findings of prominent cough during induced bronchoconstriction in association with more substantial changes in volumes than flows lead us to hypothesize that dynamic hyperinflation and gas trapping may be an important afferent stimulus for cough in both ASTHMA and COUGH. Rapidly adapting receptor activation may result from the increased pleural pressure swings associated with decreased compliance accompanied by elevated lung volume, as has been demonstrated previously in an animal model (28) .
Limitations. We recruited ASTHMA and COUGH participants from a tertiary care clinic referred for evaluation of chronic cough, thought to be because of asthma or coughvariant asthma. The demographics are therefore typical of such centers, including a predominance of women, which may limit the generalizability of our findings. Additionally, several studies have found associations between obesity and an increased propensity to develop airway responsiveness because of reduced pulmonary compliance (27, 34) and an increased tendency to develop expiratory flow limitation (17, 49, 69) . Many subjects in our study were overweight [25 kg/m 2 Ͻ body mass index (BMI) Ͻ 29.9 kg/m 2 ], which may have altered their responsiveness to methacholine. However, because there were no significant differences in BMI between the three groups, any effects of obesity on lung mechanics would likely have affected all three groups similarly. As a future direction, it would be beneficial to assess the sensory-mechanical responses to methacholine challenge in individuals with normal BMI for all three groups.
Induced sputum cell counts were available for the majority but not all participants, limiting complete characterization of the type of airway inflammation in each participant/group. However, because 86% of the COUGH participants provided adequate samples for analysis, at most 14% of the remainder might have had eosinophilic bronchitis. Furthermore, sputum cell counts were available for 86% of ASTHMA participants and 88% of COUGH participants in the subgroups who had pulmonary mechanics measured with esophageal balloon catheters. Therefore, we suggest that eosinophilic bronchitis is not fundamentally linked to our findings.
Some of the ASTHMA and COUGH participants were using inhaled corticosteroids as maintenance therapy and did not withhold therapy before methacholine testing. Inhaled corticosteroids can effectively suppress the characteristic airway inflammation in asthma, even in very low doses (3) and may be associated with decreased sensitivity of methacholine challenge. However, recent research indicates that over 90% of individuals with asthma have a PC 20 methacholine less than or equal to 8 mg/ml without withholding inhaled corticosteroids (40) . Thus, having used a methacholine threshold of 16 mg/ml in our study, diagnostic misclassification would likely have been less than 9%. Furthermore, the use of inhaled corticosteroids was similar in our ASTHMA and COUGH groups, and thus, any effect on methacholine sensitivity would be similar between the groups. We did not, however, collect information about antihistaminic use in the participants.
We utilized traditional methacholine challenge tidal breathing protocols, which include deep inspirations. Partial-flow volume loop analyses after periods of deep inspiration avoidance would need to be performed to investigate the bronchodilating and protective effects of deep inspirations in participants with asthma, cough variant asthma, and methacholineinduced cough with normal airway sensitivity.
Conclusions. This is the first detailed study to examine spirometric, lung volume, and esophageal pressure-derived pulmonary mechanics measurements during high-dose methacholine challenge in individuals with suspected cough variant asthma. Our main finding is that individuals with cough develop substantial dynamic hyperinflation and gas trapping, comparable to individuals with asthma despite relatively minor reductions in FEV 1 . This finding, coupled with the improvements in mid-to-late expiratory flows and mechanics following a DI and cough, adds new insight into the pathophysiology of cough in asthma and its variants. Gas trapping and/or pressurevolume changes associated with hyperinflation may be a stimulus to cough. Furthermore, methacholine-induced cough with normal airway sensitivity may be a clinically relevant condition, related to reversible small airway obstruction in which the bronchodilating and bronchoprotective effects of DI are preserved, rendering traditional measures of airway responsiveness normal.
